Relevant bibliographies by topics / Recombinant vaccine

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Recombinant vaccine'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Recombinant vaccine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Recombinant vaccine"

1

Jawad, J., R. W. Astuti, A. Haryanto, and N. Wijayanti. "Antibody response to Newcastle disease virus recombinant fusion protein in post-vaccinated laying hens." Journal of the Indonesian Tropical Animal Agriculture 48, no. 1 (2022): 20–27. http://dx.doi.org/10.14710/jitaa.48.1.20-27.

Full text
Abstract:
This research was aimed to analyze antibody response in laying hens post vaccinated by Newcastle Disease Virus (NDV) recombinat Fusion (F) protein which has been succesfully expressed from the F gene of local isolates of NDV from Kulon Progo strain (0663/04/2013), Yogyakarta, Indonesia. The F gene cloned into expression vector plasmid pBT7-N-His. Two types of NDV recombinant vaccine, a concentrated and pure F recombinant protein were used for vaccination. A concentrated recombinant F protein was collected from the centrifugal ultrafiltration process and a pure recombinant F protein was collect
APA, Harvard, Vancouver, ISO, and other styles
2

van Diepen, Michiel, Rosamund Chapman, Nicola Douglass, et al. "Advancements in the Growth and Construction of Recombinant Lumpy Skin Disease Virus (LSDV) for Use as a Vaccine Vector." Vaccines 9, no. 10 (2021): 1131. http://dx.doi.org/10.3390/vaccines9101131.

Full text
Abstract:
Attenuated vaccine strains of lumpy skin disease virus (LSDV) have become increasingly popular as recombinant vaccine vectors, to target both LSDV, as well as other pathogens, including human infectious agents. Historically, these vaccine strains and recombinants were generated in primary (lamb) testis (LT) cells, Madin–Darby bovine kidney (MDBK) cells or in eggs. Growth in eggs is a laborious process, the use of primary cells has the potential to introduce pathogens and MDBK cells are known to harbor bovine viral diarrhea virus (BVDV). In this study, data is presented to show the growth of an
APA, Harvard, Vancouver, ISO, and other styles
3

Prayugo, Armanda Dwi, Toto Subroto, and Wyanda Arnafia. "Efficacy of Hemagglutinin Gene of Highly Pathogenic Avian Influenza as a Vaccine Candidate in Poultry: A Review." World's Veterinary Journal 13 (March 25, 2023): 26–31. http://dx.doi.org/10.54203/scil.2023.wvj3.

Full text
Abstract:
The most prevalent fatal disease in poultry that can result in high morbidity and mortality is highly pathogenic avian influenza (HPAI), subtype H5N1. A vaccination program is the most frequent way to prevent HPAI cases in poultry, especially against the H5 subtype of HPAI. There are currently a number of avian influenza vaccines available, including recombinant and inactivated whole virus vaccines. The foundation of a recombinant vaccine is possible by the expression of an avian influenza gene of interest following insertion into a carrier vector (no pathogenic virus). A recombinant HPAI vacc
APA, Harvard, Vancouver, ISO, and other styles
4

Marra, Yasmin, and Fawziah Lalji. "Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines." Viruses 14, no. 12 (2022): 2667. http://dx.doi.org/10.3390/v14122667.

Full text
Abstract:
Infection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or “chickenpox”, or it can reactivate later in life and cause herpes zoster or “shingles”. Herpes zoster mainly occurs in older adults, causing a reduction in activities of daily living, impacting quality of life, and may lead to serious complications, including chronic pain. Two vaccines are marketed to prevent herpes zoster: the live zoster vaccine and the non-live, recombinant zoster vaccine. The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be betw
APA, Harvard, Vancouver, ISO, and other styles
5

Ertl, H. C., and Z. Xiang. "Novel vaccine approaches." Journal of Immunology 156, no. 10 (1996): 3579–82. http://dx.doi.org/10.4049/jimmunol.156.10.3579.

Full text
Abstract:
Abstract Recent advances in immunology, molecular biology, and peptide biochemistry have allowed the construction of subunit vaccines based on viral or bacterial recombinants, peptides or plasmid vectors. Although none of these approaches is currently being used for mass vaccination (with the exception or vaccinia-rabies G protein recombinant virus for wildlife immunization); several of them are undergoing clinical trials. None of these different vaccine constructs is likely to be totally effective in either the prevention of infectious diseases or immunotherapy of cancer. Recombinant viral va
APA, Harvard, Vancouver, ISO, and other styles
6

Wu, Xiao-Xin, Hang-Ping Yao, Nan-Ping Wu, et al. "Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease." Cellular Physiology and Biochemistry 37, no. 5 (2015): 1641–58. http://dx.doi.org/10.1159/000438531.

Full text
Abstract:
Ebolaviruses are highly infectious pathogens that cause lethal Ebola virus disease (EVD) in humans and non-human primates (NHPs). Due to their high pathogenicity and transmissibility, as well as the potential to be misused as a bioterrorism agent, ebolaviruses would threaten the health of global populations if not controlled. In this review, we describe the origin and structure of ebolaviruses and the development of vaccines from the beginning of the 1980s, including conventional ebolavirus vaccines, DNA vaccines, Ebola virus-like particles (VLPs), vaccinia virus-based vaccines, Venezuelan equ
APA, Harvard, Vancouver, ISO, and other styles
7

Koeberling, Oliver, Isabel Delany, and Dan M. Granoff. "A Critical Threshold of Meningococcal Factor H Binding Protein Expression Is Required for Increased Breadth of Protective Antibodies Elicited by Native Outer Membrane Vesicle Vaccines." Clinical and Vaccine Immunology 18, no. 5 (2011): 736–42. http://dx.doi.org/10.1128/cvi.00542-10.

Full text
Abstract:
ABSTRACTNative outer membrane vesicles (NOMV) (not detergent treated), which are prepared from recombinant strains with attenuated endotoxin activity and overexpressed factor H binding protein (fHbp), elicited broad serum bactericidal antibody responses in mice. The amount of overexpressed fHbp required for optimal immunogenicity is not known. In this study we prepared NOMV vaccines from LpxL1 knockout (ΔLpxL1) mutants with penta-acylated lipooligosaccharide and attenuated endotoxin activity. The recombinant strains had wild-type (1×) fHbp expression or were engineered for 3-fold- or 10-fold-i
APA, Harvard, Vancouver, ISO, and other styles
8

Hudu, Shuaibu Abdullahi, Saadatu Haruna Shinkafi, and Shuaibu Umar. "AN OVERVIEW OF RECOMBINANT VACCINE TECHNOLOGY, ADJUVANTS AND VACCINE DELIVERY METHODS." International Journal of Pharmacy and Pharmaceutical Sciences 8, no. 11 (2016): 19. http://dx.doi.org/10.22159/ijpps.2016v8i11.14311.

Full text
Abstract:
Development of an effective vaccine is of paramount important in disease prevention and control. As such, recombinant technology can serve as a gateway for the development of safe and effective vaccines that can be delivered effectively with an appropriate adjuvant. Therefore, this paper aimed to review the role of recombinant vaccine technology, new adjuvants and the challenge of vaccine delivery. Related peer-reviewed journal article searches were conducted using a subscribed database at the Universiti Putra Malaysia library, involving areas of Health Sciences and Medicine via Medline, SCOPU
APA, Harvard, Vancouver, ISO, and other styles
9

Dewidar, Abdelmonem A. A., Walid H. Kilany, Azza A. El-Sawah, et al. "Genotype VII.1.1-Based Newcastle Disease Virus Vaccines Afford Better Protection against Field Isolates in Commercial Broiler Chickens." Animals 12, no. 13 (2022): 1696. http://dx.doi.org/10.3390/ani12131696.

Full text
Abstract:
This study evaluated the efficacy of live and inactivated conventional GII LaSota and recombinant GVII Newcastle disease vaccines in commercial broilers. The experimental groups (G2–G7) were vaccinated on day 7 and day 21 of age with live vaccines from the same vaccine type “GII LaSota, GVII vaccine (A), GVII vaccine (B)” via eye drop; however, G3, G5, and G7 received a single dose from inactivated counterpart vaccines subcutaneously on day 7 of age. Vaccine efficacy was evaluated based on elicited humoral immunity, clinical protection, and reduction in virus shedding after challenge with viru
APA, Harvard, Vancouver, ISO, and other styles
10

Baldo, Aline, Amaya Leunda, Nicolas Willemarck, and Katia Pauwels. "Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2." Vaccines 9, no. 5 (2021): 453. http://dx.doi.org/10.3390/vaccines9050453.

Full text
Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used for the development of COVID-19 vaccine candidates: recombinant viral vectors, protein-based vaccines, nucleic acid-based vaccines, and inactivated/attenuated virus. Recombinant viral vector vaccine candidates represent a significant part of those vaccine candidates in clinical development, with tw
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Recombinant vaccine"

1

Hand, Nicholas. "Development of a Recombinant Attenuated Salmonella Cancer Vaccine." Thesis, The George Washington University, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10635177.

Full text
Abstract:
<p>New treatments for neuroblastoma are desperately needed; high-risk neuroblastoma patients have a less than 50% five-year survival rate despite intensive treatment. The greatest impact on improving survival rates for cancer patients in recent years is the result of a number of immunotherapeutic approaches. A proportion of high-risk neuroblastoma patients undergo spontaneous regression, possibly mediated by the immune system, indicating the potential of immunotherapies targeting neuroblastoma-associated antigens. Recombinant attenuated Salmonella vaccines (RASV) are cost-effective and have s
APA, Harvard, Vancouver, ISO, and other styles
2

Cook, Jeremy K. "Recombinant immunotargeting antigen, antibody fusions in vaccine design." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape17/PQDD_0001/NQ35130.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Herr, Roger Alan. "Evaluation of Coccidioides posadasii antigens as recombinantly expressed monovalent, divalent, and chimeric vaccine candidates." Connect to full-text via OhioLINK ETD Center, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=mco1160404292.

Full text
Abstract:
Thesis (Ph.D.)--Medical University of Ohio, 2006.<br>"In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Medical Sciences." Major advisor: Garry Cole. Includes abstract. Document formatted into pages: ii, 206 p. Title from title page of PDF document. Title at ETD Web site: Evaluation of two homologous Coccidioides posadasii antigens as recombinantly expressed monovalent, divalent, and chimeric vaccine candidates. Bibliography: pages 75-83, 116-120, 165-169, 185-204.
APA, Harvard, Vancouver, ISO, and other styles
4

Al-Zarouni, Mansour. "Expression of recombinant antigen in BCG." Thesis, University of Surrey, 2000. http://epubs.surrey.ac.uk/843308/.

Full text
Abstract:
Little is known about the effect of different modes of expression of an antigen in rBCG on immune response. An appropriate wing of the immune system, with different degrees, is activated upon encounter with a foreign antigen. Knowledge of these responses is vital to the development of future recombinant vaccine. Various E. coli-mycobacterial species shuttle vector constructs were made using a combination of mycobacterial promoters and signal sequences. Thus enabling foreign antigens to be expressed cytoplasmically or secreted outside rBCG as native proteins or membrane-associated lipoproteins.
APA, Harvard, Vancouver, ISO, and other styles
5

Danet, Nicolas. "Molecular characterisation of the recombinant Vesicular Stomatitis Virus- ZEBOV-GP virus, prototype vaccine against Ebola virus." Thesis, Lyon, 2019. http://www.theses.fr/2019LYSE1009/document.

Full text
Abstract:
Ebolavirus (EBOV) est un filovirus responsable de fièvres hémorragiques virales sévères chez l’humain, qui peuvent être létales dans 90% des cas. L’actuelle épidémie en République Démocratique du Congo et l’ampleur démesurée de l'épidémie de 2014-2016 en Afrique de l’Ouest, qui a causé la mort de plus de 11 000 personnes, ont poussé les agences sanitaires internationales à tester plusieurs approches thérapeutiques afin d’essayer d’endiguer rapidement la propagation virale et de limiter la mortalité liée au virus lors de futures épidémies. Parmi toutes les stratégies testées, le virus recombina
APA, Harvard, Vancouver, ISO, and other styles
6

Teixeira, Lais Helena. "Geração e análise da imunogenicidade de proteínas recombinantes baseadas nas diferentes formas do antígeno circumsporozoíta de Plasmodium vivax visando o desenvolvimento de uma vacina universal contra malária." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/42/42133/tde-11072014-110149/.

Full text
Abstract:
O P. vivax é a segunda espécie mais prevalente causadora de malária no mundo. Medidas de controle ineficientes exigem o desenvolvimento de novas estratégias de prevenção, como vacinas, novas drogas e novos inseticidas. O objetivo geral do trabalho foi gerar uma formulação vacinal universal com proteínas e adenovírus recombinantes capazes de induzir anticorpos contra as diferentes formas alélicas da proteína circumsporozoíta (CSP) do P. vivax. As proteínas foram produzidas em E. coli e purificadas por cromatografia de afinidade e troca iônica. A obtenção destas proteínas nos permitiu testar qua
APA, Harvard, Vancouver, ISO, and other styles
7

Saubi, Roca Narcís. "Scaling up recombinant BCG based HIV vaccine development. Lessons learned." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/400667.

Full text
Abstract:
El treball de recerca realitzat en aquesta Tesi Doctoral està dirigit a la millora del desenvolupament de la vacuna contra el VIH basada en BCG recombinant. La Tesi Doctoral inclou tres articles de recerca publicats en revistes “peer-reviewed” i una patent depositada a la Oficina Europea de Patents. Inicialment, hem avaluat la influencia de l’edat i la ruta d’immunització en la inducció de respostes immunes especifiques front a VIH i M. tuberculosis després d’immunitzar ratolins BALB/c recent nascuts i adults amb BCG.HIVA222 i reforçar-los amb Modified Virus Ankara (MVA).HIVA. Les frequ
APA, Harvard, Vancouver, ISO, and other styles
8

Ahuja, Sanjay. "Development of a recombinant protein vaccine against Plasmodium falciparum malaria /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-788-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vaghefi, Negin Gitiban. "The role of innate immunity in protection against respiratory syncytial virus (RSV)." Columbus, Ohio : Ohio State University, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1138388518.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Okay, Sezer. "Development Of Recombinant Vaccines Composed Of Plpe And Omph From Pasteurella Multocida A:3." Phd thesis, METU, 2011. http://etd.lib.metu.edu.tr/upload/12613980/index.pdf.

Full text
Abstract:
Pasteurella multocida serotype A:3 is a gram-negative bacterial pathogen which is one of the causative agents of shipping fever in cattle. In this study, ompH and two fragments of plpE gene (plpEN and plpEC) were cloned from the genomic DNA of P. multocida P-1062 (ATCC 15743, serotype A:3) and plpEN-ompH and plpEC-ompH fusions were constructed. In vitro expression of the genes was shown in HEK-293 cells. Later, full-length plpE gene was cloned and the recombinant proteins were expressed in E. coli and purified. Three DNA vaccine formulations, namely pCMV-ompH, pCMV-plpEN-ompH and pCMV-plpEC-om
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Recombinant vaccine"

1

Recombinant, Vectors in Vaccine Development (1993 Albany N. Y. ). Recombinant vectors in vaccine development: Albany NY, USA, May 23-26, 1993. Karger, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

United States. Animal and Plant Health Inspection Service. Veterinary Services. Recombinant derived pseudorabies vaccine, TK: Environmental assessment and finding of no significant impact. The Services, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Perinot, Glen. Genomic analysis of human papillomavirus types 16 and 18: Production of recombinant plasmid : part I in the production of a recombinant vaccine for human papillomavirus. Laurentian University, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

(Korea), Kŏnʼguk Taehakkyo, ed. Choryu inp'ŭlluenja yujŏnja chaejohap paeksin kaebal mit pangje yŏn'gu: Ch'oejong yŏn'gu pogosŏ = Development of recombinant avian influenza virus vaccine. Nongnimbu, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

United States. Animal and Plant Health Inspection Service. Proposed field trial in Pennsylvania of a live experimental vaccinia-vector recombinant rabies vaccine for raccoons: Environmental assessment and finding of no significant impact. U.S. Dept. of Agriculture, Animal and Plant Health Inspection Service, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Scientific Group on Development of Recombinant DNA Japanese Encephalitis and Dengue Vaccines. Report. Printed and distributed by the Regional Office for the Western Pacific of the World Health Organization, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ferran, Maureen C., and Gary R. Skuse, eds. Recombinant Virus Vaccines. Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6869-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

P, Talwar G., Rao K. V. S, and Chauhan V. S, eds. Recombinant and synthetic vaccines. Narosa Pub. House, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1947-, Isaacson Richard E., ed. Recombinant DNA vaccines: Rationale and strategy. Marcel Dekker, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

A, Liu Margaret, Hilleman Maurice R. 1942-, and Kurth Reinhard 1942-, eds. DNA vaccines: A new era in vaccinology. New York Academy of Sciences, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Recombinant vaccine"

1

Fenner, Frank. "Vaccinia Virus as a Vaccine, and Poxvirus Pathogenesis." In Recombinant Poxviruses. CRC Press, 2024. https://doi.org/10.1201/9781003574699-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brocke, Pascale, Stephan Schaefer, Karl Melber, et al. "Recombinant Hepatitis B Vaccines: Disease Characterization and Vaccine Production." In Production of Recombinant Proteins. Wiley-VCH Verlag GmbH & Co. KGaA, 2005. http://dx.doi.org/10.1002/3527603670.ch15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Marchioro, Silvana Beutinger, Simone Simionatto, and Odir Dellagostin. "Development of Mycoplasma hyopneumoniae Recombinant Vaccines." In Vaccine Design. Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3389-1_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

de Oliveira, Natasha Rodrigues, Thaís Larré Oliveira, Sérgio Jorge, and Odir Antônio Dellagostin. "Development of Human Recombinant Leptospirosis Vaccines." In Vaccine Design. Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1884-4_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kennedy, Emma, Roger Hewson, and Stuart Dowall. "Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine." In Methods in Molecular Biology. Springer US, 2024. https://doi.org/10.1007/978-1-0716-4338-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Moreira, Gustavo Marçal S. G., Clóvis Moreira, Carlos Eduardo P. da Cunha, Marcelo Mendonça, and Fabricio R. Conceição. "Recombinant Botulinum Toxoids: A Practical Guide for Production." In Vaccine Design. Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3389-1_40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Boyle, David B., and Anthony J. Radford. "Vectors for Recombinant Vaccine Delivery." In Animal Parasite Control Utilizing Biotechnology. CRC Press, 2024. https://doi.org/10.1201/9781003574880-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rodrigues, Rafael Rodrigues, Marcos Roberto Alves Ferreira, Frederico Schmitt Kremer, et al. "Recombinant Vaccine Design Against Clostridium spp. Toxins Using Immunoinformatics Tools." In Vaccine Design. Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1892-9_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Machado, Amanda Sanchez, Vivian Tamietti Martins, Maria Victoria Humbert, Myron Christodoulides, and Eduardo Antonio Ferraz Coelho. "In Silico Design of Recombinant T Peptide Epitope Vaccines for." In Vaccine Design. Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1884-4_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Burnette, W. Neal. "Perspectives in Recombinant Pertussis Toxoid Development." In Vaccine Research and Development. CRC Press, 2024. http://dx.doi.org/10.1201/9781003573838-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Recombinant vaccine"

1

Khudainazarova, N. S., D. L. Granovskiy, E. M. Ryabchevskaya, et al. "DEVELOPMENT AND CHARACTERIZATION OF A UNIVERSAL RECOMBINANT VACCINE CANDIDATE AGAINST ROTAVIRUS A." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-205.

Full text
Abstract:
Rotavirus A (RVA) remains the leading cause of severe gastroenteritis in children under 5 years old worldwide. Vaccine development against RVA is challenged by the enormous diversity of circulating RVA strains. In this study, the recombinant universal vaccine candidate was developed and characterized for the prevention of rotavirus A infection. The vaccine candidate was demonstrated to elicit an effective immune response in laboratory animals.
APA, Harvard, Vancouver, ISO, and other styles
2

Nurpeisova, Ainur, Zhandos Abay, Kamshat Shorayeva, et al. "Determining optimal conditions for growing recombinant vectors to be used in developing a bovine tuberculosis vaccine." In Research for Rural Development 2023 : annual 29th international scientific conference proceedings. Latvia University of Life Sciences and Technologies, 2023. http://dx.doi.org/10.22616/rrd.29.2023.013.

Full text
Abstract:
Two recombinant influenza A virus vectors expressing the ESAT 6 and TB10.4 mycobacterial proteins from the nonstructural (NS) gene were constructed via reverse genetics technique to develop a specific means of prophylaxis for bovine tuberculosis. We experimented to determine optimal conditions for growing recombinant vectors in Vero cell culture and chick embryos. This study established that the maximum amount of virus builds up in a Vero cell culture with the Dulbecco′s Modified Eagle′s Medium (DMEM) serum-free medium. However, using cell culture to produce vector vaccines is labourintensive
APA, Harvard, Vancouver, ISO, and other styles
3

Rak, A. Ya, P. I. Prokopenko, V. V. Muzurova, L. G. Rudenko, and I. N. Isakova-Sivak. "TIME FOR AN UPDATE: THE BENEFITS OF UPDATING THE NP COMPONENT IN WHOLE-VIRION INFLUENZA VACCINES." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-199.

Full text
Abstract:
The poor conservation (≤ 41 %) of immunogenic CD8+ T-cell (iCTL) NP epitopes of traditional vaccine donors in modern NPs and the low content (≤ 24 %) of iCTL NP epitopes of modern influenza A viruses, as well as the limited cross-specificity of anti-NP antibodies developed to recombinant proteins and during infection with different strains, suggest the importance of NP actualization in vaccine formulations.
APA, Harvard, Vancouver, ISO, and other styles
4

Jha, Richa, Shantanu Tamuly, and Mumtesh Saxena. "Calcium Phosphate Nanoparticles as Adjuvant For Recombinant Vaccine Against Salmonellosis." In Annual International Conference on Advances in Veterinary Science Research (VETSCI 2016). Global Science & Technology Forum (GSTF), 2016. http://dx.doi.org/10.5176/2382-5685_vetsci16.17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Silva, Paulo, Pedro Correia, Daiane Grugel, Victor Ferreira, and Rayane Gonçalves. "Continued Process Verification for COVID-19 Vaccine Formulation and Packaging (recombinant)." In International Symposium on Immunobiologicals. Instituto de Tecnologia em Imunobiológicos, 2022. http://dx.doi.org/10.35259/isi.2022_52269.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ivkina, D. I., A. R. Imatdinov, E. V. Dubrovskaya, and I. R. Imatdinov. "RECOMBINANT VIRUS EXHIBITING GP38 OF CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS." In OpenBio-2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-250.

Full text
Abstract:
Crimean-Congo hemorrhagic fever (CCHF) is a widespread arbovirus disease with a mortality rate of up to 40 % in humans. Despite the severity of the disease and the geographic distribution of CCHF, no vaccine or therapeutic agents are currently registered. The paper presents data on a recombinant rhabdovirus expressing a modified glycoprotein GPC of the CCHF virus, an isolate epidemiologically relevant for the Russian Federation.
APA, Harvard, Vancouver, ISO, and other styles
7

Dubrovskaya, E. V., D. I. Ivkina, and A. R. Imatdinov. "RECOMBINANT INFLUENZA A VIRUS REASSORTANT VACCINE STRAIN EXPRESSING MODIFIED RBD FRAGMENT OF SARS-COV-2 CORONAVIRUS SPIKE GLYCOPROTEIN." In OpenBio-2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-244.

Full text
Abstract:
Influenza A virus and SARS-CoV-2 virus have a high pandemic potential. Vaccination is an effective method of prevention, but existing vaccines cannot be quickly updated to match circulating virus variants. This paper describes a recombinant reassortant strain of influenza A virus expressing SARS-CoV-2 trimerized RBD, which can be used as a component of candidate multivalent vaccines.
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Xiaoping, Lijie Zhang, Lijun Sun, et al. "Antitumor Immunity Induced by Recombinant Vaccine Alpha-Fetoprotein-Heat Shock Protein 70 Complex." In 2009 3rd International Conference on Bioinformatics and Biomedical Engineering (iCBBE). IEEE, 2009. http://dx.doi.org/10.1109/icbbe.2009.5162379.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"New generation recombinant vaccine development: from idea to the product (using Newcastle virus vaccine of genotype VII as the model)." In Innovation and Application of Animal Vaccines and Health-Promotion Feed Additives for Antibiotic-Free Era in Livestock Industry. Food and Fertilizer Technology Center for the Asian and Pacific Region, 2021. http://dx.doi.org/10.56669/umhz5327.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Toropov, S. E., E. M. Ryabchevskaya, E. A. Evtushenko, N. A. Nikitin, and O. V. Karpova. "DEVELOPMENT OF RECOMBINANT NEWCASTLE DISEASE VIRUS ANTIGEN TO CREATE VACCINE AGAINST A RANGE OF CURRENT CIRCULATING STRAINS." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-202.

Full text
Abstract:
Newcastle disease virus (NDV) is the causative agent of a highly contagious disease in birds. An important issue in creating NDV vaccines is its high antigenic variability. In this study, a polyepitope recombinant antigen was designed and obtained. Immunization with the developed antigen led to the production of antibodies, which were able to interact with NDV of different strains and genotypes.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Recombinant vaccine"

1

Jaffee, Elizabeth M. Recombinant Vaccine Strategies for Breast Cancer Prevention. Defense Technical Information Center, 1999. http://dx.doi.org/10.21236/ada381767.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Barbet, Anthony F., Terry F. McElwain, Varda Shkap, Eugene Pipano, D. R. Alfred, and S. A. Hines. Development of a Recombinant DNA Derived Vaccine against Babesia bovis. United States Department of Agriculture, 1988. http://dx.doi.org/10.32747/1988.7566879.bard.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Palmer, Guy H., Eugene Pipano, Terry F. McElwain, Varda Shkap, and Donald P. Knowles, Jr. Development of a Multivalent ISCOM Vaccine against Anaplasmosis. United States Department of Agriculture, 1993. http://dx.doi.org/10.32747/1993.7568763.bard.

Full text
Abstract:
Anaplasmosis is an arthropod+borne disease of cattle caused by the rickettsia Anaplasma marginale and an impediment to efficient production of healthy livestock in both Israel and the United States. Our research focuses on development of a recombinant membrane surface protein (MSP) immunogen to replace current vaccines derived from the blood of infected cattle. The risk of widespread transmission of both known and newly emergent pathogens has prevented licensure of live blood-based vaccines in the U.S. and is a major concern for their continued use in Israel. Briefly, we accomplished the follo
APA, Harvard, Vancouver, ISO, and other styles
4

Brayton, Kelly A., Varda Shkap, Guy H. Palmer, Wendy C. Brown, and Thea Molad. Control of Bovine Anaplasmosis: Protective Capacity of the MSP2 Allelic Repertoire. United States Department of Agriculture, 2014. http://dx.doi.org/10.32747/2014.7699838.bard.

Full text
Abstract:
Anaplasmosis is an arthropod-borne disease of cattle caused by the rickettsia Anaplasmamarginale and is an impediment to efficient production of healthy livestock in both Israel and the United States. Currently, the only effective vaccines are derived from the blood of infected cattle. The risk of widespread transmission of both known and newly emergent pathogens has prevented licensure of live blood-based vaccines in the U.S. and is a major concern for their continued use in Israel. Consequently, development of a safe, effective vaccine is a high priority. Despite its drawbacks as a live, blo
APA, Harvard, Vancouver, ISO, and other styles
5

Gidengil, Courtney, Matthew Bidwell Goetz, Margaret Maglione, et al. Safety of Vaccines Used for Routine Immunization in the United States: An Update. Agency for Healthcare Research and Quality (AHRQ), 2021. http://dx.doi.org/10.23970/ahrqepccer244.

Full text
Abstract:
Objective. To conduct a systematic review of the literature on the safety of vaccines recommended for routine immunization in the United States, updating the 2014 Agency for Healthcare Research and Quality (AHRQ) report on the topic. Data sources. We searched MEDLINE®, Embase®, CINAHL®, Cochrane CENTRAL, Web of Science, and Scopus through November 9, 2020, building on the prior 2014 report; reviewed existing reviews, trial registries, and supplemental material submitted to AHRQ; and consulted with experts. Review methods. This report addressed three Key Questions (KQs) on the safety of vaccine
APA, Harvard, Vancouver, ISO, and other styles
6

McElwain, Terry, Eugene Pipano, Guy Palmer, Varda Shkap, Stephen Hines, and Douglas Jasmer. Protection of Cattle Against Babesiosis: Immunization with Recombinant DNA Derived Apical Complex Antigens of Babesia bovis. United States Department of Agriculture, 1995. http://dx.doi.org/10.32747/1995.7612835.bard.

Full text
Abstract:
Bovine babesiosis caused by Babesia bovis continues to be a significant deterrent to global livestock production. Current control methods have both biological and technical drawbacks that have stimulated research on improved methods of vaccination. This BARD project has focused on characterization of candidate Babesia bovis vaccine antigens located in the apical complex, a unique group of subcellular organelles - including rhoptries, micronemes, and spherical bodies - involved in the invation of erythrocytes. Spherical bodies and rhoptries were partially purified and their contents characteriz
APA, Harvard, Vancouver, ISO, and other styles
7

Pitt, M. L., D. Dyer, J. Hartings, and K. Batey. Efficacy of the UK Recombinant Plague Vaccine to Protect Against Pneumonic Plague in the Nonhuman Primate, Macaca Fascicularis (PRIVATE). Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada428726.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Leitner, Gabriel, and Naomi Balaban. Novel Immunotherapeutic Agent for the Treatment and Prevention of Staphylococcal Mastitis in Dairy Cows. United States Department of Agriculture, 2009. http://dx.doi.org/10.32747/2009.7709880.bard.

Full text
Abstract:
Staphylococci are the most common and costly mammary disease of dairy cattle worldwide. TRAP, a membrane associated 167AA protein, is highly conserved among staphylococci. The aims of this study were to test the safety and efficacy of recombinant TRAP (rTRAP) vaccine in dairy animals. The vaccine was safe as 2-3 subcutaneous injections of rTRAP (54–100μg) with adjuvant ISA 206 to cows and goats did not lead to any abnormal symptoms of sensitivity to the vaccine. The rTRAP vaccine was immunogenic and caused the induction of a humoral immune response that remained high for at least 160 days post
APA, Harvard, Vancouver, ISO, and other styles
9

Leitner, Gabriel, and Naomi Balaban. Novel Immunotherapeutic Agent for the Treatment and Prevention of Staphylococcal Mastitis in Dairy Cows. United States Department of Agriculture, 2009. http://dx.doi.org/10.32747/2009.7695866.bard.

Full text
Abstract:
Staphylococci are the most common and costly mammary disease of dairy cattle worldwide. TRAP, a membrane associated 167AA protein, is highly conserved among staphylococci. The aims of this study were to test the safety and efficacy of recombinant TRAP (rTRAP) vaccine in dairy animals. The vaccine was safe as 2-3 subcutaneous injections of rTRAP (54–100μg) with adjuvant ISA 206 to cows and goats did not lead to any abnormal symptoms of sensitivity to the vaccine. The rTRAP vaccine was immunogenic and caused the induction of a humoral immune response that remained high for at least 160 days post
APA, Harvard, Vancouver, ISO, and other styles
10

Lillehoj, Hyun, Dan Heller, and Mark Jenkins. Cellular and molecular identification of Eimeria Acervulina Merozoite Antigens eliciting protective immunity. United States Department of Agriculture, 1992. http://dx.doi.org/10.32747/1992.7561056.bard.

Full text
Abstract:
Coccidiosis, ubiquitous diseases of poultry, seriously impair the growth and feed utilization of livestock and poultry. Coccidiosis causes over $600 million annual losses world-wide and no vaccine is currently available. The goal of this study was to investigate the cellular and molecular mechanisms controlling protective immune responses to coccidia parasites in order to develop immunological control strategy against coccidiosis. The major findings of this study were: 1) cell-mediated immunity plays a major role in protection against coccidiosis, 2) when different genetic lines showing differ
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Recombinant vaccine' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography